|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Greven K, Petereit D, Vermorken JB and
Lanciano R: Current developments in the treatment of newly
diagnosed cervical cancer. Hematol Oncol Clin North Am. 13:275–303.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cornelio DB, Roesler R and Schwartsmann G:
Emerging therapeutic agents for cervical cancer. Recent Pat
Anticancer Drug Discov. 4:196–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sardi JE, Boixadera MA and Sardi JJ:
Neoadjuvant chemotherapy in cervical cancer: a new trend. Curr Opin
Obstet Gynecol. 17:43–47. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moore DH: Neoadjuvant chemotherapy for
cervical cancer. Expert Opin Pharmacother. 4:859–867. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tao X, Hu W, Ramirez PT and Kavanagh JJ:
Chemotherapy for recurrent and metastatic cervical cancer. Gynecol
Oncol. 110:S67–S71. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brabec V and Kasparkova J: Molecular
aspects of resistance to antitumor platinum drugs. Drug Resist
Updat. 5:147–161. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Djeu JY and Wei S: Clusterin and
chemoresistance. Adv Cancer Res. 105:77–92. 2009.PubMed/NCBI
|
|
9
|
Konishi I, Nanbu K, Mandai M, et al: Tumor
response to neoadjuvant chemotherapy correlates with the expression
of P-glycoprotein and PCNA but not GST-pi in the tumor cells of
cervical carcinoma. Gynecol Oncol. 70:365–371. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Britten RA, Liu D, Tessier A, Hutchison MJ
and Murray D: ERCC1 expression as a molecular marker of cisplatin
resistance in human cervical tumor cells. Int J Cancer. 89:453–457.
2000.PubMed/NCBI
|
|
11
|
Takara K, Sakaeda T and Okumura K: An
update on overcoming MDR1-mediated multidrug resistance in cancer
chemotherapy. Curr Pharm Des. 12:273–286. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lage H: MDR1/P-glycoprotein (ABCB1) as
target for RNA interference-mediated reversal of multidrug
resistance. Curr Drug Targets. 7:813–821. 2006.PubMed/NCBI
|
|
13
|
Xia Z, Zhu Z, Zhang L, et al: Specific
reversal of MDR1/P-gp-dependent multidrug resistance by RNA
interference in colon cancer cells. Oncol Rep. 20:1433–1439.
2008.PubMed/NCBI
|
|
14
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: an alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007.PubMed/NCBI
|
|
15
|
Yang J, Mani SA, Donaher JL, et al: Twist,
a master regulator of morphogenesis, plays an essential role in
tumor metastasis. Cell. 117:927–939. 2004.PubMed/NCBI
|
|
16
|
Iseri OD, Kars MD, Arpaci F, Atalay C, Pak
I and Gunduz U: Drug resistant MCF-7 cells exhibit
epithelial-mesenchymal transition gene expression pattern. Biomed
Pharmacother. 65:40–45. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang AD, Fan F, Camp ER, et al: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang X, Ling MT, Guan XY, et al:
Identification of a novel function of TWIST, a bHLH protein, in the
development of acquired taxol resistance in human cancer cells.
Oncogene. 23:474–482. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li QQ, Xu JD, Wang WJ, et al:
Twist1-mediated adriamycin-induced epithelial-mesenchymal
transition relates to multidrug resistance and invasive potential
in breast cancer cells. Clin Cancer Res. 15:2657–2665. 2009.
View Article : Google Scholar
|
|
20
|
Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD
and Wang LH: Twist transcriptionally up-regulates AKT2 in breast
cancer cells leading to increased migration, invasion, and
resistance to paclitaxel. Cancer Res. 67:1979–1987. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shibata K, Kajiyama H, Ino K, et al: Twist
expression in patients with cervical cancer is associated with poor
disease outcome. Ann Oncol. 19:81–85. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kwok WK, Ling MT, Lee TW, et al:
Up-regulation of TWIST in prostate cancer and its implication as a
therapeutic target. Cancer Res. 65:5153–5162. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Martin TA, Goyal A, Watkins G and Jiang
WG: Expression of the transcription factors snail, slug, and twist
and their clinical significance in human breast cancer. Ann Surg
Oncol. 12:488–496. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yan-Qi Z, Xue-Yan G, Shuang H, et al:
Expression and significance of TWIST basic helix-loop-helix protein
over-expression in gastric cancer. Pathology. 39:470–475. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Puisieux A, Valsesia-Wittmann S and
Ansieau S: A twist for survival and cancer progression. Br J
Cancer. 94:13–17. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen T: Overcoming drug resistance by
regulating nuclear receptors. Adv Drug Deliv Rev. 62:1257–1264.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Comerford KM, Wallace TJ, Karhausen J,
Louis NA, Montalto MC and Colgan SP: Hypoxia-inducible
factor-1-dependent regulation of the multidrug resistance (MDR1)
gene. Cancer Res. 62:3387–3394. 2002.PubMed/NCBI
|
|
28
|
Sampath J, Sun D, Kidd VJ, et al: Mutant
p53 cooperates with ETS and selectively up-regulates human MDR1 not
MRP1. J Biol Chem. 276:39359–39367. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
El-Osta A, Kantharidis P, Zalcberg JR and
Wolffe AP: Precipitous release of methyl-CpG binding protein 2 and
histone deacetylase 1 from the methylated human multidrug
resistance gene (MDR1) on activation. Mol Cell Biol. 22:1844–1857.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gomez-Martinez A, Garcia-Morales P,
Carrato A, et al: Post-transcriptional regulation of P-glycoprotein
expression in cancer cell lines. Mol Cancer Res. 5:641–653. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen Y, Tang Y, Wang MT, Zeng S and Nie D:
Human pregnane X receptor and resistance to chemotherapy in
prostate cancer. Cancer Res. 67:10361–10367. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang MH, Wu MZ, Chiou SH, et al: Direct
regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell
Biol. 10:295–305. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ding Z, Yang L, Xie X, et al: Expression
and significance of hypoxia-inducible factor-1 alpha and
MDR1/P-glycoprotein in human colon carcinoma tissue and cells. J
Cancer Res Clin Oncol. 136:1697–1707. 2010. View Article : Google Scholar : PubMed/NCBI
|
